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Abstract Monoaminergic dysregulation is implicated
in attention-deficit/hyperactivity disorder (ADHD), and
methylphenidate and amphetamines are the most fre-
quently prescribed pharmacological agents for treating
ADHD. However, it has recently been proposed that the
core symptoms of the disorder might be due to an imbal-
ance between monoaminergic and cholinergic systems. In
this study, we used fibroblast cell homogenates from boys
with and without ADHD as an extraneural cell model to
examine the cholinergic receptor density, that is, musca-
rinic acetylcholine receptors (mAChRs). We found that the
binding capacity (Bmax) of [
3H] Quinuclidinyl benzilate
(3H-QNB) to mAChRs was decreased by almost 50 % in
the children with ADHD (mean = 30.6 fmol/mg protein,
SD = 25.6) in comparison with controls [mean = 63.1
fmol/mg protein, SD = 20.5, p B 0.01 (Student’s unpaired
t test)]. The decreased Bmax indicates a reduced cholinergic
receptor density, which might constitute a biomarker for
ADHD. However, these preliminary findings need to be
replicated in larger ADHD and comparison cohorts.
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Introduction
Attention-deficit/hyperactivity disorder (ADHD) is the most
common neurodevelopmental disorder, with a worldwide
prevalence of about 5–7 % in childhood (Faraone et al. 2003;
Polanczyk et al. 2007). The catecholaminergic systems are
implicated in the pathophysiology of ADHD, and the phar-
macological treatment for ADHD includes central stimu-
lants that enhance the neurotransmission of dopamine and
norepinephrine through multiple actions. Interactions
between the dopaminergic and the serotonergic neurotrans-
mitter systems suggest that serotonin, in addition to dopa-
mine, is likely to be linked to the disorder (Oades 2008).
Recently, it was suggested that the core symptoms of
ADHD might be attributable to an imbalance between the
neuromodulatory effects of monoamines and acetylcholine
(Ach), implicating a monoaminergic–muscarinic receptor
interaction (Vakalopoulos 2007). ACh plays an important
role in regulating central nervous system (CNS) functions,
including memory, attention and motivation processes—all
of which have been found to be dysregulated in ADHD.
Improvement of ADHD symptoms has been reported in
adults and youths treated with cholinergic enhancers, such
as Ach partial agonists (e.g. ABT-089) and acetylcholin-
esterase (AChE) inhibitors (e.g. donepezil) (Doyle et al.
2006; Wilens et al. 2006), although results are inconclusive
(Cubo et al. 2008). Atomoxetine, a non-stimulant drug used
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for treating ADHD has been found to increase cholinergic
neurotransmission in animals, indicating a procholinergic
profile of this drug (Tzavara et al. 2006).
With respect to ADHD neurotransmission research,
there is a need for extraneural patient-derived cell models
and biochemical markers that are detectable and quantifi-
able in easily accessible tissues, but still reflecting neuronal
conditions. One such possible cell model is primary skin
fibroblasts that are being used for investigating biochemi-
cal differences in various neuropsychiatric disorders, such
as Parkinson’s disease, schizophrenia and Alzheimer’s
disease (Auburger et al. 2012; Mahadik and Mukherjee
1996; Vestling et al. 1995). Recent studies have also
demonstrated that fibroblast cells can be directly converted
into functional neurons, which further can be directed
towards distinct functional neurotransmitter phenotypes
(Pfisterer et al. 2011; Vierbuchen et al. 2010).
Skin fibroblasts represent a model of primary human
cells and comprise the polygenic risk factors of specific
patients. This model has many advantages compared to
other peripheral cell models (e.g. platelets and lympho-
cytes), one being that after several passages in culture,
fibroblasts are free from state-related changes and effects
of medications, drugs and hormones, and thus patients do
not have to be unmedicated at the time of the biopsy col-
lection (Mahadik and Mukherjee 1996).
Given the relevant impact of cholinergic dysregulation
in ADHD, the aim of the present study was to examine the
density of muscarinic acetylcholine receptors (mAChRs) in
fibroblasts from children with ADHD, and in a comparison
group, in an in vitro receptor binding assay.
Materials and methods
The study was approved by the Regional Ethics Committee
in Gothenburg, Sweden. A written and signed consent was
obtained from the parent/s and their child before per-
forming the studies.
Subjects
The index group consisted of fibroblast cell lines from 11
boys with ADHD of the combined type (inattention com-
bined with hyperactivity and impulsivity) according to the
Diagnostic and Statistical Manual of Mental Disorders
(DSM-IV) (APA 1994). They were between 10 and
11 years of age (mean 10.5 years) and treated with either
methylphenidate or atomoxetine. They were consecutively
recruited from a specialized paediatric unit for children and
adolescents with ADHD at Skaraborg’s hospital in the
south-western part of Sweden. With respect to aetiology, at
least nine of the 11 boys had a clear hereditary origin, that
is, had first-grade relatives with ADHD and uneventful
pregnancy and perinatal periods. Children with intellectual
disability or meeting full criteria for autism spectrum dis-
orders were excluded from the study. The comparison
group comprised cell lines from nine boys, between 7 and
12 years (mean 9 years), without any diagnosis of a neu-
rodevelopmental disorder. This group was recruited in
conjunction with surgery at the ear, nose and throat clinic
at Skaraborg’s hospital.
Cell culture
In order to prepare fibroblast cell homogenates to be used
in the receptor binding assays, each cell line was seeded in
T75 tissue culture flasks (Costar Europe Ltd, Costar NY,
USA) containing minimal essential medium (MEM, sup-
plemented with 10 % foetal bovine serum (FBS, Gibco),
L-glutamine (2 mM/L), penicillin (100 mg/mL), strepto-
mycin (100 mg/mL) and Amino-MaxTM (0.06 % vol/vol).
All growth media, antibiotics and FBS were obtained from
Invitrogen, Life Technologies Europe BV, Sweden. The
cells were incubated at a temperature of 37 C in the
presence of 5 % CO2 and high humidity. When the cells
reached confluence, they were harvested by trypsinization,
washed twice with phosphate-buffered saline [PBS,
National Veterinary Institute (SVA), Sweden] and diluted
in 1.5 mL of sterile Milli Q water. Protein concentrations
for each cell homogenate were determined by the Bradford
method, using bovine serum albumin as a standard
(approximately 1 mg/mL of cell protein per cell line was
used in the receptor binding assay). The cell homogenates
were stored at -20 C until used in the receptor binding
assay. Cell lines between 7th and 15th passages (i.e. the
number of splitting) were used in the experiments.
Receptor binding assay
The receptor binding assay in fibroblast cell homogenate
was done according to the modified procedure of Vestling
et al. (1995). This was done by adding 25 lL of different
concentrations (i.e. 0.1–3.0 lM) of [3H] Quinuclidinyl
benzilate (3H-QNB, specific activity 50.5 Ci/mmol,
Larodan Fine Chemicals AB, Sweden) into plastic tubes,
containing 200 lL sodium phosphate buffer (pH 7.4).
Half of the tubes contained unlabelled atropine
(1.0 9 10-4 lM, Sigma-Aldrich, USA) to correct for non-
specific binding. Fibroblast cell homogenates (25 lL;
protein concentrations approximately 1 mg/mL) were
added to the tubes, making a total volume of 250 lL.
Tubes were incubated at 22 C for 60 min and filtered
rapidly through Whatman GF/C glass fibre filters (Fisher
Scientific, Sweden) presoaked for 50 min in 0.05 % poly-
ethyleneimine solution. The filters were washed twice
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under vacuum with ice-cold sodium phosphate buffer. The
filters were then placed in scintillation vials to which
scintillation liquid was added (Optiphase Hisafe 3, Perk-
inElmer Life Science, USA) and the disintegrations per
minute (DPM) was counted by a scintillation counter
(Winspectral 1414, PerkinElmer Life Science, USA).
Calculations and statistical analysis
The specific binding of 3H-QNB was calculated by sub-
tracting the values for non-specific binding in the presence
of unlabelled atropine from those of total binding in the
absence of atropine. All incubations were performed in
duplicates and mean values were used for the calculation of
binding characteristics. The binding capacity (Bmax) and
the equilibrium dissociation constant (KD) of mAChR
antagonist QNB were determined by nonlinear regression
analysis.
Assumptions about parametric methods were met for KD
of ADHD patients, but not for KD of controls or for Bmax of
ADHD patients and controls (determined by the D0Agostino
and Pearson omnibus normality test). Therefore, the non-
parametric Mann–Whitney U test was used to compare the
Bmax and KD values between patients and controls. However,
three outliers were identified by the scaled Median Absolute
Deviation (MADE) method and by Tukey’s method; one in
the comparison group and two in the ADHD group. If
excluding these outliers, assumptions about parametric
methods were met and Student’s unpaired t test was used to
compare the Bmax and KD values between patients and con-
trols. For all statistical analyses, a significant level of 5 %
was accepted and all calculations and analyses were per-
formed using GraphPad Prism version 5 for Windows.
Results
Children with ADHD had a significantly lower binding
capacity (Bmax) of the mAChR ligand QNB in comparison
with controls (p B 0.01) when excluding the three outliers
identified by the MADE method. The KD did not differ
significantly between the two groups. These results suggest
that the children with ADHD had a reduced density
(*50 %) of mAChRs in fibroblasts, but that the affinity of
3H-QNB binding to the cholinergic receptors was not
affected (Fig. 1).
Discussion
The main finding in the present study was that children
with ADHD had a significantly lower Bmax of the mAChRs
Fig. 1 Binding characteristics of [3H] Quinuclidinyl benzilate
(3H-QNB) binding to muscarinic acetylcholine receptors (mAChRs)
in fibroblasts from children with attention-deficit/hyperactivity disor-
der (ADHD). a Illustrates the individual and median (horizontal bars)
Bmax and KD values of mAChRs in fibroblasts from children with
ADHD (n = 11) and controls (n = 9), including outliers. *Outliers,
identified by the scaled Median Absolute Deviation (MADE) method.
b Illustrates the individual and mean (horizontal bars) Bmax and KD
values of mAChRs in fibroblasts from children with ADHD (n = 9)
and controls (n = 8), excluding outliers. Bmax indicates binding
capacity, KD indicates the equilibrium dissociation constant and
mAChRs indicates muscarinic cholinergic receptors. **p B 0.01
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ligand QNB in comparison with controls. These results
suggest that the children with ADHD had a reduced density
of mAChRs in fibroblasts, which potentially could be due
to genetic (e.g. mutation/s in the genes coding for
mAChRs) and/or post-transcriptional (e.g. mRNA stability)
factors. To our knowledge, similar findings have not been
reported previously. However, three outliers were identi-
fied and we can only speculate about the reason for these
extreme values, as they were not caused by experimental
errors. The two ADHD outliers may represent different
subgroups of ADHD and at least one of these boys had no
evidence of hereditary origin. Since ADHD is a very het-
erogeneous disorder with regard to molecular genetics and
phenotypic diversity (Thome et al. 2012), the finding may
nevertheless be of relevance. However, further studies
including different subgroups of ADHD are needed in
order to draw firm conclusions.
We used fibroblast cells, derived from skin biopsies,
obtained from children with ADHD and from controls,
since these cells are considered to be a relevant experi-
mental model for functional studies in humans (Stahl 1985;
Auburger et al. 2012). Despite our finding of a difference in
the density of mAChRs in fibroblasts of children with
ADHD and controls, we can only speculate that the density
of mAChRs is also decreased in the CNS. Until now, to our
knowledge, no studies on mAChRs density have been
performed in vivo in children with ADHD.
In a recent study, muscarinic cholinergic receptor
binding (I-MR) was found to be lower (determined in
lymphocytes) in children with ADHD (Coccini et al. 2009).
This is in accordance with our findings; however, in that
study, the I-MR was only significantly decreased in girls
with ADHD, but not in boys. No explanation/theory for
these gender differences was given.
We are aware of the limitations of our study, such as a
small sample size, a small comparison group and the index
group consisting of only boys. The identification of outliers
would possibly be explained by the large heterogeneity and
complexity of molecular factors underlying ADHD.
Therefore, the results should be considered as preliminary.
Future studies have to include larger sample size consisting
of both boys and girls with hereditary and non-hereditary
ADHD.
We conclude that fibroblasts derived from patients with
ADHD offer a useful model for exploring neurological
aspects in vitro, thus allowing new hypothesis and drugs to
be tested. The indicated reduced density of mAChRs in
fibroblasts from children with ADHD may constitute a
biomarker for ADHD; however, these preliminary findings
need to be replicated.
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